China-based Zennova Pharmaceutical Group has reportedly raised close to RMB 100 million (USD 13.9 million) in a Series B financing round, with Hengbao Investment Holdings being the sole participant. The funds raised will be directed towards the commercial manufacturing and market launch of Zennova’s products, as well as new product research and development (R&D).
Investment in Comprehensive Drug Development Technology
Zennova, which specializes in the fields of ophthalmology, viruses, cardiovascular disease, and oncology, boasts the Liquipuls comprehensive new drug development technology platform. This platform is complemented by technologies such as microsphere coating and nanoparticles, which enable slow and controlled release of medications. These advancements position Zennova at the forefront of pharmaceutical innovation.
Global R&D Presence and Future Growth
The company owns R&D facilities in the US, highlighting its commitment to global research and development. With the new capital injection, Zennova is well-positioned to accelerate the development of its product pipeline and strengthen its presence in the global pharmaceutical market.-Fineline Info & Tech
